Literature DB >> 35719825

Duodenocaval Fistula: A Spontaneous Complication of Chemoradiation Therapy in Stage III Ovarian Cancer.

Marc Assaad1, Rachelle Hamadi1, Khalil El Gharib1, Racha Abi Melhem1, Yevgeniy Skaradinskiy2.   

Abstract

Duodenocaval fistula (DCF) is a rare entity which is sparsely described in the literature. Few etiologies have been listed including chemoradiation therapy. Early recognition may reduce the high mortality rate. We describe the case of a 63-year-old woman with a history of stage III ovarian cancer treated with cytoreductive surgery and adjuvant chemotherapy, including bevacizumab, who presented to the hospital because of fresh blood per rectum. One month earlier, the patient was admitted to the intensive care unit because of hemorrhagic shock secondary to a necrotic duodenal ulcer and was treated with cauterization. The patient was stable when discharged home, however, she was readmitted to the hospital because of hematemesis and hematochezia and was again in hemorrhagic shock for which the patient was urgently transfused. An abdominal computerized tomography (CT) angiography demonstrated locules of air within the intrahepatic and infrahepatic inferior vena cava (IVC), as well as evidence of communication with the duodenal lumen, and a thrombus within the IVC. The patient was evaluated by the surgical oncology and vascular teams, who deemed the patient inoperable. Our case describes ovarian malignancy, treated by radiation, leading to duodenitis, with subsequent ulcer formation. The co-administration of bevacizumab delayed gastric healing and promoted ulcer perforation favoring fistula formation.
Copyright © 2022, Assaad et al.

Entities:  

Keywords:  bevacizumab toxicity; chemoradiation therapy; duodenocaval fistula; ovarian cancer; perforated duodenal ulcer; retroperitoneal tumor

Year:  2022        PMID: 35719825      PMCID: PMC9199580          DOI: 10.7759/cureus.25031

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  12 in total

Review 1.  Radiological diagnosis of duodenocaval fistula: a case report and literature review.

Authors:  Yong Guo; Yan-Qun Zhang; Wei Lin
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Duodenocaval fistula in peptic ulceration.

Authors:  J G Geraghty; E Coveney; T E Kennedy; P J O'Dwyer; J J Murphy
Journal:  Gut       Date:  1991-04       Impact factor: 23.059

Review 3.  Duodenocaval fistula complicating peptic ulcer disease: case report and review of the literature.

Authors:  C A Miller; W S Melvin
Journal:  Surgery       Date:  1996-06       Impact factor: 3.982

4.  Duodenocaval fistula after treatment with bevacizumab.

Authors:  Anna Curell; María José Gómez-Jurado; José Luis Sánchez; Eloy Espin
Journal:  Med Clin (Barc)       Date:  2019-06-05       Impact factor: 1.725

5.  Spontaneous Duodenocaval Fistula During Chemo-Radiotherapy.

Authors:  Xavier Tenezaca-Sari; Marvin García-Reyes
Journal:  Eur J Vasc Endovasc Surg       Date:  2019-08-07       Impact factor: 7.069

6.  [Duodenocaval fistula: an unusual form of peptic ulcer revelation].

Authors:  M L Ousmane; P Herbecq; M Nyunga; G Vignozzi; C Lemaire
Journal:  Ann Fr Anesth Reanim       Date:  2005-09-23

7.  Staged surgical treatment of a primary duodenocaval fistula in a patient with metastatic nonseminomatous germ cell tumor.

Authors:  Annie Boisvert; Raymond Labbé; Pascal Rhéaume
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2018-10-24

8.  [Duodenocaval fistula].

Authors:  Miguel Correia; Luísa Moreira; Fernando Moreira
Journal:  Acta Med Port       Date:  2011-12-29

9.  Operative and long term results after surgery for chronic radiation enteritis.

Authors:  J M Regimbeau; Y Panis; J L Gouzi; P L Fagniez
Journal:  Am J Surg       Date:  2001-09       Impact factor: 2.565

Review 10.  Duodenocaval fistula: a late complication of retroperitoneal irradiation and vena cava replacement.

Authors:  Ganesha B Perera; Samuel E Wilson; Philip S Barie; John A Butler
Journal:  Ann Vasc Surg       Date:  2004-01-20       Impact factor: 1.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.